264 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. (12th April 2019) - Emery, Paul; Baraliakos, Xenofon; Braun, Jürgen; Deodhar, Atul; Poddubnyy, Denis; Delicha, Eumorphia-Maria; Talloczy, Zsolt; Porter, Brian